Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 96

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 96
---
 2024, the Special Committee held a meeting with representatives of Dechert and Goldman Sachs in attendance.
Representatives of Goldman Sachs briefed the Special Committee on their work to assist the Special Committee in its review with Enfusion management of the preliminary long-range plan and projections that Enfusion management had prepared for
Enfusion. The Special Committee provided representatives of Goldman Sachs with feedback to relay to management regarding the long-range plan and projections for Enfusion. Representatives of Goldman Sachs updated the Special Committee on unsolicited
and general inbound communications of interest from parties potentially interested in pursuing a transaction with Enfusion.

On
October 4, 2024, the Special Committee held a meeting with representatives of Dechert in attendance. Representatives of Dechert reviewed certain considerations that could be relevant to the Special Committee’s review of all strategic
alternatives, including considerations relating to their fiduciary duties to Enfusion and Enfusion Stockholders. Representatives of Goldman Sachs then joined the meeting and briefed the Special Committee on their work to assist the Special Committee
in its review of all strategic alternatives. The Special Committee also reviewed the preliminary long-range plan and projections for Enfusion that had been prepared by Enfusion management and discussed the assumptions underlying that plan. The
Special Committee provided representatives of Goldman Sachs with feedback to relay to management regarding the long-range plan and

62

projections for Enfusion. Representatives of Goldman Sachs updated the Special Committee on inbound indications of interest from parties potentially interested in pursuing a transaction with
Enfusion.

On October 11, 2024, the Special Committee held a meeting with representatives of Dechert and Goldman Sachs in
attendance. Representatives of Goldman Sachs shared their views as to Enfusion’s strategic alternatives, including whether it was the right time to explore a sale of Enfusion or another strategic alternative to the standalone plan.
Representatives of Goldman Sachs also shared their preliminary financial analysis perspectives. The Special Committee reviewed the preliminary long-range plan and projections for Enfusion that had been prepared by Enfusion management and discussed
the assumptions underlying that plan. Representatives of Goldman Sachs discussed 21 financial sponsors and 19 strategic parties that the Special Committee could include in a strategic transaction process and made recommendations to the Special
Committee about what parties should be included in the strategic transaction process, if the Special Committee determined to proceed with such a process, based on, among other things, the parties’ demonstrated and perceived interest in a
potential transaction with Enfusion, ability to finance a potential transaction, investment strategy and history and appetite for mergers